Positron emission tomography-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer, researchers say. READ MORE
Use of active surveillance for very low-risk prostate cancer rose 15.7% over a 3-year span and continues to rise, but rates are still low.
The US Food and Drug Administration approved a lower dose of a previously approved therapy for prostate cancer after reviewing a post-marketing study.
Patients with high-risk prostate cancer initiating long-term hormone therapy will likely benefit from two new treatments with comparable efficacy and safety profiles.
Older men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even those who may be too old to benefit from the treatment.
Research in Review
Research suggests that age can impact the risk of disease progression in low-risk prostate cancer managed with active surveillance.
Current National Comprehensive Cancer Network guidelines and Gleason scores cannot reliably stratify patients with risk of prostate cancer for the presence or absence of pathogenic germline variants.
Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy significantly improves overall survival and radiographic progression-free survival in patients with high-risk metastatic hormone-naïve prostate cancer.
A diagnostic magnetic resonance imaging (MRI) scan followed by an MRI-guided biopsy strategy is more cost-effective than an invasive transrectal ultrasound for detecting prostate cancer.